Navigation Links
EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
Date:1/28/2008

Combination of Panzem(R) NCD and Avastin(R) May Slow Tumor Growth

ROCKVILLE, Md., Jan. 28 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presentation of interim results for its Phase 2 multi-center study combining Panzem(R) NCD with Avastin(R) (bevacizumab) in patients with advanced or metastatic carcinoid tumors. The data were presented by principal investigator, Matthew Kulke, M.D., from the Dana-Farber Cancer Institute, during the 2008 Gastrointestinal Cancers Symposium being held in Orlando, Florida.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Thirty-one patients received oral Panzem(R) NCD daily in combination with Avastin(R) administered intravenously every other week. Of the 29 evaluable patients, 27 patients (87%) had stable disease and 2 patients (7%) had progressive disease as their best response. Fourteen of the 31 patients have been treated for at least six months, and 9 of the 14 have been treated for over one year. Results demonstrate that the combination of Panzem(R) NCD and Avastin(R) is well tolerated in advanced carcinoid tumor patients. The current analysis includes median follow up time over 8 months. Median progression-free survival and overall survival have not yet been reached. Enrollment in the trial is closed and 9 patients remain on study.

Carolyn F. Sidor, M.D., M.B.A., EntreMed's Vice President and Chief Medical Officer, commented on the results, "This study was designed to evaluate the combination of two antiangiogenic agents, Panzem(R)
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
2. EntreMed Appoints Senior Vice President of Research and Development
3. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
4. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. BAI Retail Delivery Conference Softpro Presents Next Generation Signature Tablet
7. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
8. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
9. Arpida Presents Preclinical Data on AR-2474 at ICAAC
10. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
11. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... , June 02, 2015 Research and Markets ... "Bioburden Testing Market by Product , Test, Application ... to their offering. The bioburden testing market ... $354.4 Million in 2014, growing at a CAGR of ... of products, the microbial limit testing market is segmented ...
(Date:6/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/2b7734/molecular ) has announced the addition ... Strategy and Forecasts - 2015 to 2019" report ... Market Size, Strategy and Forecasts - 2015 to 2019" ... of pages of information including a complete list of ... help understand test pricing in detail. See ...
(Date:6/2/2015)... -- Meet ARGUS, The World,s First Contactless ... People. Analyze emotions and predict actions. Explore a New ... first Responsive-RPG: "The Eye: Genesis".      (Photo: ... , https://www.youtube.com/watch?v=B1ZEtAZ2Yf8 Imagine ... feelings - and those of others. Being able to ...
(Date:6/2/2015)... 2015 Cirrascale Corporation ®, ... rackmount computing and storage infrastructure for conventional and ... its high density scale-out, two-in-one video delivery and ... . The high density, two-in-one system supports the ... with Intel® Iris™ Pro graphics P6300 and provides ...
Breaking Biology Technology:Bioburden Testing Market 2015 - Global Forecasts to 2019 2Global Molecular Diagnostics Report 2015-2019 - Market Size, Strategy and Forecasts 2Global Molecular Diagnostics Report 2015-2019 - Market Size, Strategy and Forecasts 3ARGUS - The World's First Inner Emotion Scanner Launches on KickStarter 2ARGUS - The World's First Inner Emotion Scanner Launches on KickStarter 3Cirrascale® Announces Support for Intel® Xeon® Processor E3-1200 v4 Product Family; Launches Server Offering Optimized for Low Cost-per-Stream Transcoding Applications 2Cirrascale® Announces Support for Intel® Xeon® Processor E3-1200 v4 Product Family; Launches Server Offering Optimized for Low Cost-per-Stream Transcoding Applications 3
... Conference Call and Webcast Today at 1:00 pm ... FRANCISCO, Calif., June 30 Anesiva,Inc. (Nasdaq: ... its first,commercial product, Zingo(TM) (lidocaine hydrochloride monohydrate) powder,intradermal ... that reduces the pain associated with peripheral,intravenous (IV) ...
... today,received information from Danske Bank, that the Danske Bank ... - through,acquisition today of 502,300 shares now owns 1,804,514 ... to 5,99% of the share capital and 5,99%,of the ... Exiqon,s corporate mission is to combine leading-edge scientific,expertise in ...
... with ADHD ages 6 to 65, RARITAN, N.J., ... and behavioral disorder treated in children(1), and,according to the ... 70 percent of children with ADHD continue to exhibit ... about eight million, or,one in 20, adults in the ...
Cached Biology Technology:Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children 2Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children 3Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children 4Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children 5FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults 2FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults 3FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults 4
(Date:5/21/2015)... The Sync Project™ , a global ... today announced a collaborative partnership with Berklee,s Institute ... on collaboration on original research, joint course development and ... collaboration, The Sync Project and BerkleeICE are exploring the ... the 2015-2016 academic year.  The course ...
(Date:5/19/2015)... , May 19, 2015 ... announced the addition of the  "Genetic Testing ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, ... in-depth analysis of the current and future ... gene-based tests, their working principles and types ...
(Date:5/11/2015)... a well-rounded UAS delegation representing private industry, government, and academia, ... AUVSI,s Unmanned 2015 conference last week in Atlanta ... UAS industry met with over 200 hundred people from companies ... ecosystem. "Our message is clear and consistent," ... Rich Knoll . "If you want to fly UAS, you ...
Breaking Biology News(10 mins):The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3Global Genetic Testing Market Outlook 2018 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2
... the remote highlands of eastern Suriname discovered 24 species ... with florescent purple markings and other amphibians, fish and ... the findings from a 2005 expedition led by Conservation ... in 2006 demonstrate the value of exploring unknown regions ...
... so many people continue to suffer from life-altering, chronic pain ... answer -- and an effective treatment -- has long eluded ... haven’t worked very well. , A Northwestern University ... to be an old memory trace that essentially gets stuck ...
... cauliflower While orange cauliflower may seem unappealing to ... have identified the genetic mutation behind the unusual hue. ... including maize, potato, rice, sorghum and wheat. , ... Li Li and colleagues -- and described in the ...
Cached Biology News:Researchers find 24 species believed new to science in Suriname rainforest 2Old memory traces in brain may trigger chronic pain 2Old memory traces in brain may trigger chronic pain 3Discovery in orange cauliflower may lead to more nutritious crops 2
... The Partec Cell Counter Analyser counts cells ... the CCA detects only cells, so that ... the results.,While passing through a 250 m ... fluorescence light signal which is used as ...
... Results Laser Capture Microdissection (LCM) enables ... accuracy of molecular assays by starting with ... structures isolated from whole tissue or cytology ... 1996 at the National Institutes of Health ...
Mouse monoclonal antibody raised against a partial recombinant DHX8. NCBI Entrez Gene ID = DHX8...
... antibody raised against a partial ... Immunogen: K6HF (NP_004684, 141 ... recombinant protein with GST tag. ... NM_004693 ...
Biology Products: